Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo
nivolumab · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
The single-agent unresectable or metastatic melanoma indication expanded to patients aged 12 or older.
LAMPGEN ANALYSIS
Why it matters
The supplement made nivolumab monotherapy available to an adolescent population under the label.
What research teams should watch
Confirm age and weight, and distinguish the single-agent indication from the ipilimumab combination.
PRIMARY RECORDS